about
Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer TreatmentsThe influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments.Peptide pills for brain diseases? Reality and future perspectives.Emerging Nanonisation Technologies: Tailoring Crystalline Versus Amorphous Nanomaterials.New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting.Engineering Synergistically Active and Bioavailable Cost-effective Medicines for Neglected Tropical Diseases; The Role of Excipients.Efficacy of a poly-aggregated formulation of amphotericin B in treating systemic sporotrichosis caused by Sporothrix brasiliensis.Engineering Oral and Parenteral Amorphous Amphotericin B Formulations against Experimental Trypanosoma cruzi Infections.Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating.Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.Engineering Nanomedicines into Safe and Effective Therapeutics.Modelling and shadowgraph imaging of cocrystal dissolution and assessment of in vitro antimicrobial activity for sulfadimidine/4-aminosalicylic acid cocrystals.Cocrystal habit engineering to improve drug dissolution and alter derived powder properties.Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme.A multivariate investigation into the relationship between pharmaceutical characteristics and patient preferences of bioequivalent ibuprofen tabletsOral Particle Uptake and Organ Targeting Drives the Activity of Amphotericin B NanoparticlesThe oral delivery of amphotericin BAnalgesic and anti-inflammatory controlled-released injectable microemulsion: Pseudo-ternary phase diagrams, in vitro , ex vivo and in vivo evaluationImpact of Substrate Properties on the Formation of Spherulitic Films: A Case Study of Salbutamol SulfatePolymorphism in Sulfadimidine/4-Aminosalicylic Acid Cocrystals: Solid-State Characterization and Physicochemical PropertiesUnresponsiveness of Experimental Canine Leishmaniosis to a New Amphotericin B FormulationAmphotericin B Formulations – The Possibility of Generic CompetitionA novel formulation of solubilised amphotericin B designed for ophthalmic useEvaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral LeishmaniasisTransferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scaleEffect of enantiomerism on the bioequivalence of a new ibuprofen 600-mg tablet formulation obtained by roller compactionAntifungal and Antiparasitic Drug DeliveryPredicting the critical quality attributes of ibuprofen tablets via modelling of process parameters for roller compaction and tablettingPersonalised 3D Printed Medicines: Optimising Material Properties for Successful Passive Diffusion Loading of Filaments for Fused Deposition Modelling of Solid Dosage FormsRepurposing Butenafine as An Oral Nanomedicine for Visceral LeishmaniasisDesigning Fast-Dissolving Orodispersible Films of Amphotericin B for Oropharyngeal CandidiasisIncreased Efficacy of Oral Fixed-Dose Combination of Amphotericin B and AHCC® Natural Adjuvant against AspergillosisOral Fixed-Dose Combination Pharmaceutical Products: Industrial Manufacturing Versus Personalized 3D Printing
P50
Q36764312-1208C693-7FEC-44EA-A1F2-E684A0CF4D25Q38001740-4C06F1F0-9593-4E9A-8017-CDAFE6A0C05CQ38096036-5A88ACFB-3B40-4521-9717-99821F8E477FQ38516038-65A9A08A-6937-4759-9DD3-6192E28684EAQ38977703-E1946053-2404-407A-B197-7561CDA1B8EAQ39235791-698934A0-04F0-4CAA-B084-3AD2313A96F4Q39447195-748BBA6A-CA8A-4089-93AD-1659F9DCC073Q40187292-21A0D44F-FC91-48D2-A546-FC54A28FEC71Q40332720-7A2F1C84-F7E9-447D-9672-4C2A2895D071Q47292255-04F1E0B9-9AC8-461C-A748-47B0E3C6D274Q48032209-313A7284-82C9-4758-BD70-404B0FA19982Q48144807-A6E05414-7CF5-464C-8721-DF7250E7BA3CQ48617603-57358D4D-001C-4E8B-8043-9D24872E212FQ51706707-419DB7AE-FC6B-43EC-9360-7AFB9DE3B8CFQ51747317-34E4EEAC-3C1F-46A1-8695-EB6601154FFDQ54970083-14EDF424-54DC-496D-898E-8C00448587F0Q57069441-B3833D5C-B30B-4B50-8E08-E68176758704Q57610399-9B4B6205-4274-4FAC-8009-2D25CEA36BB2Q57610422-F9B57D22-899F-4A02-A117-7250884FF069Q57617479-6D834D8A-987B-4C78-8E72-9C90AEA3C7F3Q57617481-C0976481-8392-4A9B-8FC9-7C7F8EB0EA83Q57617482-89A6B9C5-5801-435A-8933-9338E0A45C37Q57617483-692B0E1B-292C-40E0-8198-4CA1D6D4909CQ57617488-C33EEEE6-5993-4DED-80D3-815260CD7A84Q57617490-79F4C12E-6F6A-4CB4-8F21-DE0BFC012B6CQ90597373-8D3E16AD-E1E1-45C8-8C4E-EAA8C379B050Q91070973-9B6BD02A-DD5B-43F3-A32E-2C35C36A9E37Q91393043-6DFFC684-494F-4239-AE62-7FF7373CAF5EQ91669644-76B82E20-F353-40B6-AD9C-1D59934BFB88Q91920147-9409AE19-DD58-4362-8B54-89F404F27A6BQ91923828-692E31E1-4BF8-4FB0-A544-28FB992CF49EQ92081242-CD457A20-0B6F-40CB-9293-5C2CE2E2E53FQ92372617-1191E848-0F45-43EE-8904-21B6DB218A68Q93102983-929A8E2A-1DFE-4A2F-A3F3-1C9CDECC5C01Q96581839-A2D5658B-660C-4BA1-8B7D-4C8652469CD8
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dolores R Serrano
@ast
Dolores R Serrano
@en
Dolores R Serrano
@es
Dolores R Serrano
@nl
Dolores R Serrano
@sl
type
label
Dolores R Serrano
@ast
Dolores R Serrano
@en
Dolores R Serrano
@es
Dolores R Serrano
@nl
Dolores R Serrano
@sl
prefLabel
Dolores R Serrano
@ast
Dolores R Serrano
@en
Dolores R Serrano
@es
Dolores R Serrano
@nl
Dolores R Serrano
@sl
P1053
I-8862-2016
P106
P21
P31
P3829
P496
0000-0002-0475-8420